23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
October 05 2022 - 8:21AM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company with a mission to help
people access, understand, and benefit from the human genome, today
announced that it will present a trials-in-progress poster
presentation on 23ME-00610, an investigational antibody targeting
CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 37th
Annual Meeting to be held in Boston, MA from November 8–12, 2022.
The trials-in-progress poster presentation will summarize the
study design for the ongoing first-in-human Phase 1 study assessing
the safety, tolerability and preliminary anticancer activity of
23ME-00610, the Company's wholly-owned investigational therapy
targeting CD200R1, in patients with advanced solid malignancies.
Included in the presentation will be details on the expansion phase
of the study (part B) in patients with specific types of advanced
solid tumors.
Title: A Phase 1 Dose Escalation and Expansion
Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with
Advanced Solid Malignancies.Session: Annual
Meeting Regular Poster Abstract PresenterAbstract/Poster
Number: 758Location: Hall C (The poster
will also be available to view under the investors section of the
Company’s website at investors.23andme.com).Date and
Time: Friday, November 11, 2022 - 9:00 a.m. – 8:30 p.m.
ET
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit www.23andMe.com. 23andMe is the
only company with multiple FDA authorizations for over-the-counter
genetic health risk reports, and in particular the only company FDA
authorized to provide, without physician involvement, genetic
cancer risk reports and medication insights on how individuals may
process certain commonly prescribed medications based on their
genetics. The Company has also created the world’s largest
crowdsourced platform for genetic research, which it is using to
pursue drug discovery programs rooted in human genetics across a
spectrum of disease areas.
About 23ME-0061023ME-00610 is a high-affinity
humanized monoclonal antibody that is designed to bind to the
CD200R1 receptor and prevent the interaction of CD200 and CD200R1.
The CD200–CD200R1 axis is an immunological checkpoint that plays a
pivotal role in maintenance of immune tolerance. CD200R1 is an
inhibitory receptor expressed on T cells and myeloid cells while
CD200, the ligand for CD200R1, is highly expressed on certain
tumors. Binding of tumor associated CD200 to CD200R1 leads to
immune suppression and decreased immune cell killing of cancer
cells. Preclinical data indicate that this mechanism has the
potential to restore the ability for both T-cells and myeloid cells
to kill cancer cells.
The Phase 1 study is an open-label study to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, and preliminary
clinical activity of 23ME-00610 in patients with advanced solid
malignancies who have progressed on all available standard
therapies. Clinical trials registry (clinicaltrials.gov):
NCT05199272.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, funding for continued
operations, cash reserves, projected costs, plans, and objectives
of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K and in its subsequent reports on Forms 10-Q and
8-K. The statements made herein are made as of the date of this
press release and, except as may be required by law, 23andMe
undertakes no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Mar 2024 to Apr 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Apr 2023 to Apr 2024